UK's NICE does not recommend tucatinib for HER2-positive metastatic breast cancer.

Zdroj:	PharmacoEconomics & Outcomes News. 11/13/2021, Vol. 891 Issue 1, p37-37. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink